BIORA THERAPEUTICS, INC. short interest in 2024
In 2024, BIORA THERAPEUTICS, INC.'s disclosed short interest ran from 2.50% of shares outstanding on 12 Jan 2024 to 6.42% on 29 Nov 2024, a change of +3.92 percentage points. The year's high was 6.42% on 29 Nov 2024 and its low 2.50% on 12 Jan 2024, averaging 4.64% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.83 days on 30 Aug 2024. Full history: BIORA THERAPEUTICS, INC..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024
2024 in figures
- Start of year
- 2.50% (12 Jan 2024)
- End of year
- 6.42% (29 Nov 2024)
- Change
- +3.92 pp
- High
- 6.42% (29 Nov 2024)
- Low
- 2.50% (12 Jan 2024)
- Average
- 4.64%
- Highest days to cover
- 15.83 (30 Aug 2024)
- SEC filings marked
- 8
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 2.50% | 1.97 | |
| 31 Jan 2024 | 2.69% | 2.05 | |
| 15 Feb 2024 | 3.01% | 3.73 | |
| 29 Feb 2024 | 4.75% | 1.67 | |
| 15 Mar 2024 | 4.98% | 3.05 | |
| 28 Mar 2024 | 4.42% | 4.65 | results (8-K) |
| 15 Apr 2024 | 4.60% | 1.68 | 10-K filed |
| 30 Apr 2024 | 4.83% | 6.31 | |
| 15 May 2024 | 4.53% | 6.41 | 10-Q filed, results (8-K) |
| 31 May 2024 | 4.59% | 3.43 | |
| 14 Jun 2024 | 4.65% | 6.27 | |
| 28 Jun 2024 | 4.53% | 8.11 | |
| 15 Jul 2024 | 4.37% | 5.59 | |
| 31 Jul 2024 | 5.12% | 7.03 | |
| 15 Aug 2024 | 4.53% | 6.25 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 5.51% | 15.83 | |
| 13 Sep 2024 | 5.91% | 14.19 | |
| 30 Sep 2024 | 5.83% | 8.14 | |
| 15 Oct 2024 | 3.86% | 5.89 | |
| 15 Nov 2024 | 5.71% | 2.01 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 6.42% | 2.38 |
See also: BIORA THERAPEUTICS, INC.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.